Leucettines, a family of pharmacological inhibitors of DYRKs and CLKs kinases derived from the marine sponge Leucettamine B

Leucettines, a family of pharmacological inhibitors of DYRKs and CLKs kinases derived from the marine sponge Leucettamine B

Bibliographic Details
Main Authors:	Tahtouh, T, Fedorov, O, Lozach, O, Carreaux, F, Bazureau, J, Meunier, J, Maurice, T, Knapp, S, Meijer, L
Format:	Conference item
Published:	2012

Similar Items

Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B: modulation of alternative pre-RNA splicing.
by: Debdab, M, et al.
Published: (2011)

Selectivity, cocrystal structures, and neuroprotective properties of leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid leucettamine B.
by: Tahtouh, T, et al.
Published: (2012)

Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview
by: Mattias F. Lindberg, et al.
Published: (2021-06-01)

Cdc-Like Kinases (CLKs): Biology, Chemical Probes, and Therapeutic Potential
by: Paula Martín Moyano, et al.
Published: (2020-10-01)

Novel Inverse Binding Mode of Indirubin Derivatives Yields Improved Selectivity for DYRK Kinases.
by: Myrianthopoulos, V, et al.
Published: (2013)

DYRK1A inhibitors leucettines and TGF-β inhibitor additively stimulate insulin production in beta cells, organoids, and isolated mouse islets.
by: Barbara Pucelik, et al.
Published: (2023-01-01)

Design and Microwave Synthesis of New (5<i>Z</i>) 5-Arylidene-2-thioxo-1,3-thiazolinidin-4-one and (5<i>Z</i>) 2-Amino-5-arylidene-1,3-thiazol-4(5<i>H</i>)-one as New Inhibitors of Protein Kinase DYRK1A
by: Khadidja Bourahla, et al.
Published: (2021-10-01)

A Practical Approach to New (5Z) 2-Alkylthio-5-arylmethylene-1-methyl-1,5-dihydro-4H-imidazol-4-one Derivatives
by: Jean Pierre Bazureau, et al.
Published: (2011-08-01)

Structures of Down syndrome kinases, DYRKs, reveal mechanisms of kinase activation and substrate recognition.
by: Soundararajan, M, et al.
Published: (2013)

Structures of down syndrome kinases, DYRKs, reveal mechanisms of kinase activation and substrate recognition
by: Soundararajan, M, et al.
Published: (2013)

Development of New Meridianin/Leucettine-Derived Hybrid Small Molecules as Nanomolar Multi-Kinase Inhibitors with Antitumor Activity
by: Mohamed H. Elsherbeny, et al.
Published: (2021-09-01)

Acridone alkaloids from Glycosmis chlorosperma as DYRK1A inhibitors
by: Beniddir, M.A.A., et al.
Published: (2014)

The DYRK Family of Kinases in Cancer: Molecular Functions and Therapeutic Opportunities
by: Jacopo Boni, et al.
Published: (2020-07-01)

The kinase DYRK1A reciprocally regulates the differentiation of Th17 and regulatory T cells
by: Bernard Khor, et al.
Published: (2015-05-01)

Insights from the protein interaction Universe of the multifunctional “Goldilocks” kinase DYRK1A
by: Varsha Ananthapadmanabhan, et al.
Published: (2023-10-01)

Discovery and characterization of selective and ligand-efficient DYRK inhibitors
by: Henderson, SH, et al.
Published: (2021)

Dual specificity kinase DYRK3 regulates cell migration by influencing the stability of protrusions
by: Martina Ramella, et al.
Published: (2024-04-01)

DYRK1A Kinase Inhibitors Promote β-Cell Survival and Insulin Homeostasis
by: Agata Barzowska, et al.
Published: (2021-08-01)

The Kinase Mirk/dyrk1B: A Possible Therapeutic Target in Pancreatic Cancer
by: Eileen Friedman
Published: (2010-07-01)

Dual Specificity Kinase DYRK3 Promotes Aggressiveness of Glioblastoma by Altering Mitochondrial Morphology and Function
by: Kyeongmin Kim, et al.
Published: (2021-03-01)

DYRK-family kinases regulate Candida albicans morphogenesis and virulence through the Ras1/PKA pathway
by: Jessie MacAlpine, et al.
Published: (2023-12-01)

Selectivity Profiling and Biological Activity of Novel β-Carbolines as Potent and Selective DYRK1 Kinase Inhibitors.
by: Katharina Rüben, et al.
Published: (2015-01-01)

Kinase inhibitor selectivity profiling using differential scanning fluorimetry.
by: Fedorov, O, et al.
Published: (2012)

DYRK1A promotes viral entry of highly pathogenic human coronaviruses in a kinase-independent manner.
by: Madison S Strine, et al.
Published: (2023-06-01)

P324: PHARMACOLOGIC INHIBITION OF DYRK1A RENDERS HIGH-RISK KMT2A-R ALL SENSITIVE TO VENETOCLAX
by: C. Hurtz, et al.
Published: (2022-06-01)

How to Separate Kinase Inhibition from Undesired Monoamine Oxidase A Inhibition—The Development of the DYRK1A Inhibitor AnnH75 from the Alkaloid Harmine
by: Anne Wurzlbauer, et al.
Published: (2020-12-01)

The Omnipresence of DYRK1A in Human Diseases
by: Estelle Deboever, et al.
Published: (2022-08-01)

DYRK1A antagonists rescue degeneration and behavioural deficits of in vivo models based on amyloid-β, Tau and DYRK1A neurotoxicity
by: Bangfu Zhu, et al.
Published: (2022-09-01)

Kinase Inhibitors from Marine Sponges
by: Ana Zivanovic, et al.
Published: (2011-10-01)

Structure of dystrophia myotonica protein kinase.
by: Elkins, J, et al.
Published: (2009)

Structure of dystrophia myotonica protein kinase.
by: Elkins, J, et al.
Published: (2009)

Insights for the development of specific kinase inhibitors by targeted structural genomics.
by: Fedorov, O, et al.
Published: (2007)

Functional Roles of DYRK2 as a Tumor Regulator
by: Yuta Mochimaru, et al.
Published: (2023-10-01)

Loss of the DYRK1A Protein Kinase Results in the Reduction in Ribosomal Protein Gene Expression, Ribosome Mass and Reduced Translation
by: Chiara Di Vona, et al.
Published: (2023-12-01)

A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
by: Fedorov, O, et al.
Published: (2007)

Development of Novel Fluorinated Polyphenols as Selective Inhibitors of DYRK1A/B Kinase for Treatment of Neuroinflammatory Diseases including Parkinson’s Disease
by: Gian Luca Araldi, et al.
Published: (2023-03-01)

Pharmacological inhibition of LIM kinase stabilizes microtubules and inhibits neoplastic growth.
by: Prudent, R, et al.
Published: (2012)

Mining public domain data to develop selective DYRK1A inhibitors
by: Henderson, SH, et al.
Published: (2020)

Corrigendum: Gut and spleen anomalies associated with DYRK1A syndrome
by: I. Infantino, et al.
Published: (2024-02-01)

Ocular Phenotype Associated with <i>DYRK1A</i> Variants
by: Cécile Méjécase, et al.
Published: (2021-02-01)